<DOC>
	<DOCNO>NCT01477580</DOCNO>
	<brief_summary>This study determine whether least one formulation experimental dengue vaccine ( V180 ) safe cause immune response .</brief_summary>
	<brief_title>Study Dengue Vaccine ( V180 ) Healthy Adults ( V180-001 )</brief_title>
	<detailed_description />
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Selected In good health Voluntarily agree participate give write informed consent Able read , understand , complete study questionnaire Able complete schedule visit comply study procedure Access telephone Agrees avoid unusual , vigorous exercise 72 hour dose study vaccine/placebo 15 day dose Weighs ≥110 pound ( 50 kg ) body mass index ( BMI ) 19 32 kg/m^2 No fever ( temperature ≥100.4°F/38.0°C ) 72 hour prior vaccination Females reproductive potential agree remain abstinent use 2 acceptable method birth control enrollment 6 week last dose study vaccine/placebo Selected History receive flavivirus vaccine ( e.g . Japanese encephalitis , tickborne encephalitis , yellow fever ) plan receipt vaccine study period History flavivirus infection serologic evidence flavivirus infection , include West Nile , dengue , yellow fever , Saint Louis encephalitis ( available ) , Kunjin , Murray Valley encephalitis , Japanese encephalitis History residence cumulative period &gt; 1 year country dengue , Japanese encephalitis virus , yellow fever virus common Planned travel area dengue common 28 day receive last dose study vaccine/placebo Known hypersensitivity component dengue vaccine Abuse drug alcohol within 12 month prior screen Pregnant breastfeeding , expect conceive time enrollment 6 week last dose study vaccine/placebo Positive serum test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C antibody Known , suspect , history immunocompromise History malignancy within 5 year prior enrollment Poorly control diabetes mellitus Use immunosuppressive therapy ( except topical inhaled/nebulized steroid ) Receipt license nonlive vaccine within 14 day prior first dose study vaccine/placebo plan receive license nonlive vaccine time receive first dose 28 day receive last dose study vaccine/placebo Receipt license live vaccine within 30 day prior first dose study vaccine/placebo plan receive license live vaccine time receive first dose 28 receive last dose study vaccine/placebo Received investigational drug vaccine within 2 month prior first dose study vaccine/placebo History receive 1 dos investigational dengue vaccine Participation another clinical study within 42 day prior enrollment , plan participate another clinical study enrollment 1 year last dose study vaccine/placebo Planned donation egg sperm time enrollment 28 day last dose study vaccine/placebo Prior receipt blood transfusion blood product within 6 month prior first dose study vaccine/placebo Hospitalization acute illness within 3 month prior first dose vaccine/placebo</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>